Symbicort FDA Approval History
FDA Approved: Yes (First approved July 21, 2006)
Brand name: Symbicort
Generic name: budesonide and formoterol
Dosage form: Inhaler
Company: AstraZeneca
Treatment for: Asthma, Maintenance, COPD, Maintenance
Symbicort (budesonide and formoterol) is a combination of a corticosteroid and a long-acting bronchodilator indicated for the long-term maintenance treatment of asthma and the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Development timeline for Symbicort
| Date | Article |
|---|---|
| Jan 26, 2017 | Approval Symbicort Approved for the Treatment of Asthma in Patients 6 to 12 Years of Age |
| Feb 27, 2009 | Approval FDA Approves Symbicort for Chronic Obstructive Pulmonary Disease (COPD) |
| Jul 22, 2006 | Approval AstraZeneca’s Symbicort (budesonide/formoterol) Treatment For Asthma Approved By The FDA |
| Sep 23, 2005 | AstraZeneca Submits New Drug Application (NDA) to FDA for Symbicort Maintenance Treatment of Asthma |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.